비은계 항균 창상 피복재 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Non-silver Antimicrobial Wound Dressing Market Summary

The global non-silver antimicrobial wound dressing market size was estimated at USD 529.41 million in 2025 and is projected to reach USD 739.11 million by 2033, growing at a CAGR of 4.35% from 2026 to 2033. The non-silver antimicrobial wound dressing industry is driven by the rising prevalence of chronic wounds and the increasing number of surgical procedures requiring effective infection control.

Concerns over antimicrobial resistance and the cytotoxicity of silver-based products are accelerating the shift toward alternatives like iodine, honey, and PHMB. Growing awareness of advanced wound care and an aging population further support market growth.

The rising prevalence of chronic wounds, such as diabetic foot ulcers and pressure ulcers, is significantly driving demand for non-silver antimicrobial wound dressings. These wounds require long-term management and effective infection control, which increases the use of safer, less cytotoxic alternatives such as PHMB and iodine-based dressings. As the patient pool continues to grow, the need for advanced, sustainable wound care solutions is accelerating market growth.

Furthermore, the increasing incidence of venous leg ulcers is driving the demand for non-silver antimicrobial wound dressings, as these wounds require prolonged treatment and consistent infection control. Non-silver options such as PHMB and iodine-based dressings are preferred for their safety, reduced cytotoxicity, and suitability for long-term use. As the burden of venous ulcers rises, the need for effective, patient-friendly wound care solutions continues to drive market growth.

The increasing number of surgical procedures and traumatic injuries is driving demand for non-silver antimicrobial wound dressings, as effective infection prevention is critical for post-operative and acute wound care. These dressings offer safer alternatives with lower cytotoxicity, making them suitable for repeated use during recovery. As surgical volumes and injury cases rise, the need for reliable and advanced wound management solutions continues to grow.

Technological advancements in wound care materials are driving the non-silver antimicrobial wound dressing industry by enabling the development of more effective, biocompatible, and targeted antimicrobial solutions such as PHMB and iodine-based formulations. These innovations enhance healing outcomes, reduce infection risks, and support wider adoption across both clinical and home care settings.

As a result, the growing burden of chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, along with rising surgical and trauma cases and continuous advancements in wound care materials, is collectively driving the demand for non-silver antimicrobial wound dressings. In addition, the increasing preference for safer, low-cytotoxic alternatives and the need for effective long-term wound management solutions are further supporting sustained market growth.

Global Non-silver Antimicrobial Wound Dressing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-silver antimicrobial wound dressing market report based on the product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Honey
• Iodine
• Chitosan
• PHMB
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
  • Diabetic foot ulcers
  • Pressure ulcers
  • Deep tissue injury
  • Venous leg ulcers
  • Other chronic wounds
• Acute Wounds
  • Surgical & traumatic wounds
  • Burns
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Home Healthcare
• Physician's Office
• Nursing Homes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Non-Silver Antimicrobial Wound Dressing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of chronic wounds
    • 3.2.1.2. Growing burden of diabetes and vascular diseases
    • 3.2.1.3. Increasing incidence of surgical and traumatic wounds
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of advanced wound care products
    • 3.2.2.2. Limited awareness and delayed diagnosis in emerging regions
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Rising adoption of home healthcare and self-care treatments
    • 3.2.3.2. Increasing focus on antimicrobial resistance (AMR)
    • 3.2.3.3. Government initiatives and healthcare funding
    • 3.2.3.4. Shift toward alternative antimicrobial agents
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Stringent regulatory requirements
• 3.3. Non-Silver Antimicrobial Wound Dressing Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Non-Silver Antimicrobial Wound Dressing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Non-Silver Antimicrobial Wound Dressing Market: Product Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Non-Silver Antimicrobial Wound Dressing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Honey
  • 4.4.1. Honey market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Iodine
  • 4.5.1. Iodine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Chitosan
  • 4.6.1. Chitosan market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. PHMB
  • 4.7.1. PHMB market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Non-Silver Antimicrobial Wound Dressing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Non-Silver Antimicrobial Wound Dressing Market: Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Non-Silver Antimicrobial Wound Dressing Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 5.4. Chronic Wounds
  • 5.4.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Diabetic foot ulcers
    • 5.4.2.1. Diabetic foot ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Pressure ulcers
    • 5.4.3.1. Pressure ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Deep tissue injury
    • 5.4.4.1. Deep tissue injury market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Venous leg ulcers
    • 5.4.5.1. Venous leg ulcers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.6. Other chronic wounds
    • 5.4.6.1. Other chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Acute Wounds
  • 5.5.1. Acute Wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Surgical & traumatic wounds
    • 5.5.2.1. Surgical & traumatic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Burns
    • 5.5.3.1. Burns market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Non-Silver Antimicrobial Wound Dressing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Non-Silver Antimicrobial Wound Dressing Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 6.3. Global Non-Silver Antimicrobial Wound Dressing Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Home Healthcare
  • 6.6.1. Home healthcare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Physician's Office
  • 6.7.1. Physician's office market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. Nursing Homes
  • 6.8.1. Nursing homes market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Non-Silver Antimicrobial Wound Dressing Market: Regional Estimates & Trend Analysis by Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait non-silver antimicrobial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2025
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. Molnlycke AB
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Cardinal Health
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Advanced Medical Solutions Group plc
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Coloplast Corp
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Leukoplast (Essity)
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Smith+Nephew
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. PAUL HARTMANN AG
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Gentell.
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Winner Medical Co., Ltd.
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. AdvaCare Pharma
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives